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INTRODUCTION
Schistosomiasis is a chronic disease affecting human beings 
through 76 countries in several parts of the world and is argu-
ably the most important human parasitic disease in terms of 
mortality. It is estimated that 207 million people are already 
infected by various species of schistosomes [1]. There are 779 
millions exposed to the risk of infection [2] and the disease is 
responsible for 280,000 deaths per year in endemic areas [3].
Despite the existence of the highly effective antischistosomal 
drug praziquantel, drug treatment and other existing control 
measures are costly and have failed to eliminate the incidence 
of infection, morbidity, and mortality due to schistosomiasis 
infection [4]. This is in part due to the inability of chemother-
apy to prevent new infection and failure of previously infected 
individuals to develop an effective immune response against 
the parasite [5]. Therefore, a long-term disease control strategy 
is needed combining mass chemotherapy with a protective vac-
cine. The development of an effective vaccine against schisto-
some is a critical stage, despite the fact that progress has been 
relatively slow, the successful use in animals of attenuated vac-
cines combined with recent recombinantly derived schisto-
some antigens, suggested that development of a safe and effec-
tive vaccine is feasible [6].
Vaccines in schistosomiasis using homologous antigens have 
been studied broadly in experimentally infected mammalian 
hosts than that of heterologous antigens. Numerous authors 
using a variety of experimental models have demonstrated cross-
ed immunity. Native Fasciola hepatica fatty acid binding protein 
(FABP) (=nFh12) was shown to be a potential vaccine against 
both Schistosoma mansoni and F. hepatica [7]. C57/BL6 mice 
immunized with nFh12 had a significant reduction in Schisto­
soma bovis worm burden recoveries (96 and 87% reductions 
over control in 2 separate experiments) [8]. MAbs developed 
against Fasciola gigantica FABP all cross react with S. mansoni 
whole worms extract [9]. 
This work aimed to evaluate the efficacy of native F. gigantica 
FABP as a prophylactic agent against S. mansoni infection in 
CD1 mice.
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Abstract: Although schistosomicidal drugs and other control measures exist, the advent of an efficacious vaccine remains 
the most potentially powerful means for controlling this disease. In this study, native fatty acid binding protein (FABP) from 
Fasciola gigantica was purified from the adult worm’s crude extract by saturation with ammonium sulphate followed by 
separation on DEAE-Sephadex A-50 anion exchange chromatography and gel filtration using Sephacryl HR-100, respec-
tively. CD1 mice were immunized with the purified, native F. gigantica FABP in Freund’s adjuvant and challenged subcuta-
neously with 120 Schistosoma mansoni cercariae. Immunization of CD1 mice with F. gigantica FABP has induced heterol-
ogous protection against S. mansoni, evidenced by the significant reduction in mean worm burden (72.3%), liver and in-
testinal egg counts (81.3% and 80.8%, respectively), and hepatic granuloma counts (42%). Also, it elicited mixed IgG1/Ig-
G2b immune responses with predominant IgG1 isotype, suggesting that native F. gigantica FABP is mediated by a mixed 
Th1/Th2 response. However, it failed to induce any significant differences in the oogram pattern or in the mean granuloma 
diameter. This indicated that native F. gigantica FABP could be a promising vaccine candidate against S. mansoni infection.
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MATERIALS AND METHODS
Animals 
Six to 8-week-old female albino CD1 mice (24±2 g) were 
bred and maintained at the Schistosome Biological Supply Pro-
gram, Theodor Bilharz Research Institute, Giza, Egypt (SBSP/
TBRI). They were kept under standard laboratory care. Animal 
experiments have been carried out according to the internation-
ally valid guidelines and ethical conditions [10]. 
Parasites 
Adult F. gigantica worms were obtained from the bile ducts 
and gall bladders of naturally infected cattle livers. The flukes 
were washed 4 times with PBS (pH 7.4) at room temperature 
to remove all traces of blood and bile. Cercariae of an Egyptian 
strain of S. mansoni were obtained from SBSP/TBRI, and used 
for infection immediately after shedding from Biomphalaria al­
exandrina snails. 
Purification of F. gigantica fatty acid binding protein (FABP)
FABP was purified from the crude extracts by a combination 
of 3 different methods: ammonium sulphate precipitation, ion 
exchange chromatography on diethylaminoethyl (DEAE) sep-
hadex A-50, and gel filtration using sephacryl HR-100, respec-
tively, according to Timanova et al. [11].
Adult F. gigantica were homogenized at 4˚C, in 2 volumes of 
20 mM Tris-HCL buffer (BDH Chemicals, England) contain-
ing 5 mM phenylmethylsulfonyl fluoride (PMSF) as a protease 
inhibitor (Sigma Aldrich, St. Louis, Missouri, USA) at 20,000 
rpm using IKA T20 homogenizer (IKA, Staufen, Germany). The 
homogenate was centrifuged at 30,000 rpm for 30 min at 4˚C 
and the supernatant was subjected to purification with 70% 
ammonium sulfate saturation. The post-saturation superna-
tant was then dialyzed overnight against 3 changes of 40 vol-
umes of 10 mM Tris HCl buffer (pH 6.5), the dialysate was 
loaded on to a DEAE Sephadex A-50 column that had previ-
ously been equilibrated with the same buffer. The substance of 
interest (FABP) was washed out of the gel and not adsorbed 
under these conditions. The eluate was concentrated and sub-
jected to sephacryl HR-100 gel filtration column equilibrated 
with 10 mM Tris HCl buffer (pH 8.2). The elution is carried 
out under gravity, 1 ml fractions were collected and absorbance 
was measured at 280 nm. The fractions were then analyzed by 
SDS-PAGE. 
SDS-PAGE
To analyze samples at different purification steps, SDS-PAGE 
0.75-mm thick 12% vertical slab gels was performed under re-
ducing conditions as described by Laemmli [12]. Samples were 
mixed with an equal volume of sample buffer (0.125 M Tris 
Hcl, 4% [w/v] SDS, 20% [v/v] glycerol, 10% [v/v] mercapto-
ethanol, 0.1% [w/v] bromophenol blue as a tracking dye) and 
immediately boiled for 5 min. All reagents used were of elec-
trophoresis grade (Bio-Rad Laboratories, Richmond, Califor-
nia, USA). Low Mw kit standard protein (Bio-Rad) was pre-
pared in parallel. The gels were stained with coomassie bril-
liant blue 0.05%. 
Immunization and challenge infection 
A batch of 55 mice was divided into 4 groups. Group I: Nor-
mal healthy controls (10 mice). Group II: Infected control group 
(15 mice). Mice were subcutaneously (SC) injected with 120 S. 
mansoni cercariae. Group III: Immunized group (10 mice). Mice 
were intraperitoneally (IP) injected with 100 µg of FABP emul-
sified in complete Freund’s adjuvant (CFA) (Pierce, Rockford, 
Illinois, USA). Booster doses (50 µg/ml in equal volume of in-
complete Freund's adjuvant (IFA, Pierce) was administered at 
week 2 and 3 after the initial dose. Group IV: Immunized in-
fected group (20 mice). Mice were IP injected with 100 µg of 
FABP emulsified in CFA. Booster doses (50 µg/ml in equal vol-
ume of IFA was administered at week 2 and 3 after the first 
dose. At 1 week after the last boost, all animals were challenged 
through the SC injection with 120 S. mansoni cercariae. At week 
8 post-infection (PI), all mice groups were sacrificed and sub-
jected to examinations on the following parameters: 
Parasitological parameters
Worm burden
Hepatic and portomesenteric vessels were perfused [13] to 
recover worms for subsequent counting. Following perfusion, 
numbers and sex of the adult worms were determined. They 
were counted either by direct visualization or under a stereo-
microscope. Protection was calculated comparing the number 
of worms recovered from each group of mice with their respec-
tive controls, using the formula below: 
% Protection=
Mean worms of control group 
-Mean worms of test group
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Tissue egg load
The number of eggs per gram of tissues (liver and intestine) 
was studied according to the procedure achieved by Cheever 
[14].
Oogram pattern
The percentages of immature, mature, and dead ova in the 
small intestines were computed from a total of 100 eggs per 
intestinal segment and classified according to the categories 
previously defined by Pellegrino et al. [15].
ELISA 
Total and subclasses of anti-FABP IgM and IgG (H+L chains), 
IgG1, IgG2a, IgG2b, and IgG3 were measured using indirect ELI-
SA based on the method of Engvall and Perlman [16]. ELISA 
microtitre plates were coated with 100 µl/well of 3 µg/ml FABP 
in carbonate/bicarbonate buffer. Sera were diluted to 1:250. 
Alkaline phosphatase (AKP)-labeled anti-mouse IgM (µ chain 
specific) and IgG (H+L chains) specific conjugate solution 
(Promega, Madison, Wisconsin, USA), were used at dilution 
1:5,000 and 1:2,500, respectively. For the isotype determina-
tion experiment, isotype specific AKP-labeled anti-mouse mAb 
to mouse IgG1 (1:1,000), IgG2a (1:1,000), AKP-labeled rat 
mAb to mouse, IgG2b (1:3,000) and IgG3 (1:1,000) conju-
gates were used. The reaction was measured at optical density 
(OD) values 405 nm using an ELISA reader (Bio-Rad Micro-
plate Reader).
Histopathological procedures
Livers of mice were fixed in 10% buffered formalin, process-
ed into paraffin blocks, serially cut at 4 µm thickness and stain-
ed with hematoxylin and eosin. Hepatic granuloma measure-
ments were done according to von Lichtenberg [17] using an 
ocular micrometer for those containing a central ovum only. 
Counting was carried out in 5 successive microscopic fields 
(10×10) in serial tissue sections of more than 250 µm apart.
Statistical analysis 
Data are presented as mean±SD. The means of different 
groups were compared globally using 1 way analysis of vari-
ance (ANOVA), the mean difference between the 2 groups was 
calculated using the Student’s t-test. Data were considered sig-
nificant if P-value was <0.05. SPSS computer program (version 
12 windows) was used for data analysis.
RESULTS
FABP purification
The profile of F. gigantica adult worm crude extract (lane 2) 
and its purified FABP (lanes 3 and 5) was shown in Fig. 1. The 
washed fractions obtained after purification by DEAE sepha-
dex A-50 ion exchange column chromatography was assayed 
by 12% SDS. FABP was represented by a single band at 14.5 
kDa with traces of other proteins at 34, 50, and 80 kDa (Fig. 1, 
lane 3). The protein content of these fractions was 2.5 mg/ml, 
and the other fractions were found to be a 17 kDa protein (Fig. 
1, lane 4). 
The fractions containing FABP were further purified through 
a Sephacryl HR-100 gel filtration column. The eluted FABP in 
the collected fraction was assayed by 12% SDS-PAGE, and the 
purified FABP was represented by a single band at 14.5 kDa 
(Fig. 1, lane 4). The protein content of FABP by these methods 
was 1.5 mg/ml as a purification result from starting protein con-
tent of crude extracts of F. gigantica adult worms (20 mg/ml).
Parasitological parameters
Immunization of mice with F. gigantica FABP antigen induc-
ed a high significant reduction in the mean total number of 
worm burden on comparing the immunized infected group to 
the infected control group (P<0.001), with percent reduction 
(PR) 72.3% (Table 1). Moreover, A highly significant reduction 
KDa
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Fig. 1. Analysis of different F. gigantica antigen extracts by 12% 
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in the mean total number of hepatic and intestinal egg loads 
was observed on comparing the immunized infected group to 
the infected control group (P<0.001), with PR of 81.3% and 
80.8%, respectively (Table 1). The FABP antigen administra-
tion had insignificant effects on the oogram pattern (mature, 
immature, and dead eggs). 
Immunological parameters
We investigated which type of immune response is induced 
by multiple immunizations with FABP in Freund’s adjuvant. 
The detection of IgG1 as a Th2 marker and IgG2a/2b as a Th1 mar-
ker was performed by ELISA. Multiple immunizations with 
FABP in Freund’s adjuvant induced a highly significant increase 
in total IgG, IgG1, and IgG2b antibodies in immunized groups 
and infected immunized group (P<0.001), with IgG1 isotype 
predominating, while no significant increase was seen in IgG2a 
and IgG3 antibodies. There was also a significant increase in 
IgM levels in immunized and infected immunized groups (Ta-
ble 2).
Histopathological parameters
The mean number of hepatic granuloma of infected control 
group recorded 16.2±3.7 which was reduced in the immuniz-
ed infected group after multiple administration of FABP anti-
gen to be 10.0±3.5 with PR=42%, showing a highly signifi-
cant reduction (P<0.001) compared to infected control group. 
In contrast, the mean hepatic granuloma diameter (MGD) in 
infected control mice group recorded 180.0±5.6. Repeated 
administration of FABP dose induced no significant reduction 
in the MGD in the infected mice (165.0±6.5) (Fig. 2).
DISCUSSION
Schistosomiasis is the most important human helminth in-
fection in terms of morbidity and mortality. Despite 2 decades 
of wide spread chemotherapy with safe and effective drugs, the 
number of individuals with active schistosomiasis worldwide 
remains at about 200 million. Generally, severe symptoms of 
the disease appear only in people who harbor large numbers 
of parasites, so if a vaccine is effective in reducing a patient’s 
burden of worms by 50% or more, this will be reflected in a 
reduction in the numbers of eggs retained in the tissues. Thus 
it can dramatically reduce the number of severe cases of the 
disease and morbidity [18]. Consequently, vaccine strategies 
represent an essential component for the future control of schis-
tosomiasis as an adjunct to chemotherapy. Since morbidity, 
rather than sterile immunity is the target, only a partial protec-
tive vaccine is required. 
The development of an effective vaccine against schistosomes 
is a critical stage, despite the fact that progress have been rela-
tively slow, the successful use in animals of attenuated vaccines 
combined with recent recombinant derived Schistosoma anti-
Table 1. Different parasitological parameters detected at week 8 PI in different animal groups
Animal group Total worm 
burden 
Mean no. of ova/g tissue Oogram pattern Mean no. of 
hepatic granuloma Liver  Intestine  Mature Immature Dead
Infected group 37.0±4.5 7,200±1,276 8,979±462 60.0±14.8 35.0±15.8 5.0±2.6 16.2±3.7
Immunized
  infected group
10.0±4.5 1,343±522 1,724±575 55.0±12.5 38.0±15.3 7.0±3.5 10.0±3.5
% Reduction 72.3
a 81.3
a  80.8
a  8.5 8.0↑  28.5↑ 42.0
a 
Data are expressed as mean±SD or percent.
aStatistically significant difference at P<0.001 compared to infected control group. 
Table 2. Serum IgM, IgG (H+L), and various IgG isotypes levels against FABP antigen in different mice groups
Animal group
Mean absorbance (405 nm)±SD
IgM IgG (H+L) IgG1 IgG2a IgG2b IgG3
Normal group 0.25±0.057 0.42±0.03 0.26±0.05 0.37±0.01 0.31±0.04 0.38±0.06
Infected control group 0.30±0.08 0.81±0.07
a  0.30±0.03 0.40±0.05 0.34±0.04 0.41±0.03
Immunized group 0.37±0.09
b 1.1±0.05
a  0.63±0.08
a  0.63±0.08
a 0.43±0.03
a 0.44±0.06
a 
Immunized infected group 0.36±0.08
c 1.49±0.14
c  0.73±0.13
c  0.40±0.06 0.55±0.12
c  0.40±0.07
aStatistically significant difference at P<0.001 compared to the normal group; 
bStatistically significant difference at P<0.05 compared to the normal 
group; 
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gens and partial immunity developed against schistosomiasis 
in individuals living in endemic areas suggest that the devel-
opment of a safe and effective vaccine is possible [4,19]. Vac-
cines in schistosomiasis using homologous antigens have been 
studied extensively in experimentally infected mammalian hosts; 
vaccines using heterologous antigens have received compara-
tively less attention [20]. Cross immunity has been demon-
strated among Schistosoma species and different parasitic trem-
atodes [21-25]. One of the most studied cross reactive antigens 
is the native Fh12 and recombinant rFh15 F. hepatica FABP [20]. 
Sirisriro et al. [9] developed mAb against rFABP of F. gigantica. 
These mAb reacted with at least two isoforms of native pro-
teins at Mw 14.5 kDa that were present in the tegumental anti-
gen, crude worm extracts, and the excretory-secretory (ES) pro-
duct and cross-reacted with a 14.5 kDa antigen present in the 
whole body extract of S. mansoni. Whether this can be translat-
ed into cross reactive immunoprophylaxis against both S. man­
soni and F. gigantica is to be determined. So, our idea was to 
evaluate the efficacy of the native F. gigantica FABP as a prophy-
lactic agent against S. mansoni infection in CD1 mice.
The result of the present study proved that native heterolo-
gous F. gigantica FABP significantly protects CD1 mice against 
challenge infection with S. mansoni. Multiple immunizations 
with native heterologous F. gigantica FABP via IP route in Fre-
und’s adjuvant had a strong immunoprophylactic effect against 
challenge infection with S. mansoni in CD1 mice. The protec-
tive effects were evidenced by reductions in the mean worm 
burden, ova count, and granuloma count in immunized in-
fected group as compared to infected control group. Multiple 
immunizations of mice with FABP recorded a high significant 
reduction in worm burden (72.3%), which is the gold stan-
dard for anti-schistosomal vaccine development as it also had 
an adverse effect on the liver and intestinal egg count which 
results in lower number of eggs recovered from liver and intes-
tinal tissues. Administration of FABP resulted in a very high 
and significant PR in liver and intestinal egg count (81.3% and 
80.8%, respectively). This reduction reduces the number of 
eggs trapped in the hepatic tissues and hence decreases the 
number of hepatic granuloma by 42%. In contrast, it failed to 
induce any significant differences in the oogram pattern or in 
the mean granuloma diameter. These results were in agree-
ment with those obtained by Abáne et al. [8] who reported 
that native F. hepatica FABP (Fh12) could elicit protective im-
munity in C57/BL6 mice. In 2 separate experiments, reduc-
tions in worm burden (96 and 87%) were found when Fh12 
was inoculated with Freund’s adjuvant; however, no protection 
was obtained in NRMI and BALB/c mice. The recombinant 
form of the antigen (rFh15) administrated in Freund’s also in-
duced significant levels of protection against heterologous chal-
lenge with S. bovis in C57/BL6 mice, 72% less worms than con-
trols, and milder liver lesions was observed [8]. Furthermore, 
Hamed [26] reported that F. hepatica ES products in Freund’s 
adjuvant significantly protect mice against S. mansoni infection 
evidenced by the significant reduction in worm burden, ova 
Fig. 2. Hepatic granuloma diameter. (A) Hepatic sections of S. mansoni infected control animals at week 8 PI showed that granulo-
mas were large, scattered of both cellular and fibrocellular types. Mild degree of hydropic degeneration was observed in many of the 
hepatocytes. (B) Hepatic sections of immunized infected group showed milder fibrosis, and chronic perivascular inflammation was 
still observed.
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count, granuloma size, and numbers. FABP is considered as 
one of the major components of the helminth ES products.
In the humoral response, the change of immunoglobulin 
isotypes is regulated by the cytokines that segregate the T help-
er cells. IL-4 induces the change from IgM to IgG1 and IgE in B 
lymphocytes, a Th2 antibody response. On the other hand, 
IFN-γ required for Th1 T cell-dependent IgG2a/2b antibodies re-
sponses [27,28].
The highly significant increase in IgM and IgG antibodies, 
and more specifically IgG1 and IgG2b isotypes could indicate 
that the immunoprophylactic effect of the native F. gigantica 
FABP induced an immune response mediated by both cell-
mediated and humoral (Th1/Th2) mechanisms which impede 
or interrupt the development of the infection with S. mansoni 
in some way in this strain of mice. 
The protection obtained with 14.5 kDa native heterologous 
F. gigantica FABP was higher than that obtained with other ho-
mologous candidate antigens for anti-Schistosoma vaccines. The 
percentage protection using native F. gigantica FABP was great-
er (70%) in terms of the reduction of worm burden which were 
never achieved using homologous antigens of S. mansoni, IrV5 
(50%-70%) [29], Sm28GST (40%-50%) [30], Sm14 (65%) 
[31], paramyosin (26-33%) [32], Sm29 (51%) [33], and Sm-
p80 (39%-57%) [34]. The reduction in worm burden leads to 
a high reduction in liver and intestinal egg count which exceed 
80%, this ratio was greater than the anti-fecundity effects of 
Sm28- and Sh28-GST (50% reduction in tissue egg load) and 
consequently there was a less number of liver granuloma (42% 
reduction in granuloma number). Further studies should be 
directed toward the use of recombinant form of F. gigantica 
FABP in experimental infection of S. mansoni and Schistosoma 
haematobium. 
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